Halozyme Therapeutics, Inc. (HALO) News
Filter HALO News Items
HALO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HALO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest HALO News From Around the Web
Below are the latest news stories about HALOZYME THERAPEUTICS INC that investors may wish to consider to help them evaluate HALO as an investment opportunity.
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons WhyHalozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes. |
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study DataSana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients. |
Are You a Growth Investor? This 1 Stock Could Be the Perfect PickWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock UpHalozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise. |
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?Investors need to pay close attention to Halozyme (HALO) stock based on the movements in the options market lately. |
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth TodayWhy investing for the long run, especially if you buy certain popular stocks, could reap huge rewards. |
SpringWorks Therapeutics Stock Gets A RS Rating LiftSpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating |
Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-BellHalozyme Therapeutics (HALO) shares were 5% higher premarket Wednesday after the company raised its |
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial GuidanceHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance. The Company also announced it has recently entered into a new $250 million accelerated share repurchase (ASR) program under its previously announced $750 million share repurchase program. |
Are You a Momentum Investor? This 1 Stock Could Be the Perfect PickThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |